Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
Visit the News Hub
Aim is for commercialization in US, Europe, Japan
Washington University in St. Louis has licensed the rights to develop, manufacture and commercialize its proprietary COVID-19 nasal vaccine in the United States, Europe and Japan to Ocugen Inc., a US-based biotechnology company.
” data-medium-file=”https://medicine.wustl.edu/wp-content/uploads/NasalVaccine-300×200.jpg” data-large-file=”https://medicine.wustl.edu/wp-content /uploads/NasalVaccine-700×467.jpg”/>Getty Images
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is on the path to becoming available in the US, Europe and Japan. The university has licensed the rights to develop, manufacture and commercialize its proprietary COVID-19 vaccine in the United States, Europe and Japan to Ocugen Inc., a US-based biotechnology company focused on developing and commercializing novel genes and cell therapies and vaccines.
A nasal vaccine is thought to provide greater protection against the virus than current injectable vaccines, which help prevent severe illness and death but do little to prevent infections, especially as highly contagious newer variants continue to spread. The advantage of the nasal vaccine is that it delivers a boost to immunity in the nose and upper respiratory tract, right where the virus enters the body, thereby potentially preventing infections altogether.
Ocugen intends to work closely with US government agencies tasked with pandemic preparedness and response to initiate clinical trials and manufacture the intranasal vaccine. The company also is interested in the potential for the nasal vaccine to be a universal booster, regardless of a person’s previous COVID-19 vaccination history.
“Despite the many challenges of a global pandemic, our accomplished, dedicated faculty have continued to push the boundaries of discovery,” said Dedric Carter, PhD, Washington University’s vice chancellor for innovation and chief commercialization officer. “The licensing of the nasal vaccine technology highlights the culture of innovation we’re developing at Washington University. All of our faculty’s extraordinary efforts in research innovation are with the goal of translating insights from the laboratory into improvements in the health and lives of people in our communities and across the globe.”
The Washington University nasal vaccine technology was previously licensed to Bharat Biotech International Limited in 2020 for development in India and limited parts of the world. This September, health authorities in India approved the vaccine for emergency use in that country, making it the world’s first intranasal vaccine for COVID-19 to be approved.
The investigational nasal vaccine was co-developed by Washington University scientists David T. Curiel, MD, PhD, the Distinguished Professor of Radiation Oncology, and Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, of molecular microbiology and of pathology & immunology, with members of their laboratories. They started collaborating in early 2020, as the virus that causes COVID-19 first began its wildfire-like spread across the globe.
Curiel had long worked on using harmless, deactivated cold viruses called adenoviruses to deliver gene therapies for cancer and other diseases. Diamond, an expert in viruses and infectious diseases, was already studying the virus that causes COVID-19 in his laboratory, having obtained a sample from the National Institutes of Health (NIH) in the first weeks of the pandemic. Curiel and Diamond teamed up to create and test their adenovirus-based nasal vaccine for COVID-19.
“In recent months we have seen COVID-19 continue to spread — despite high levels of vaccination the US, Europe and Japan have achieved,” Diamond said. “Because the vaccine can be delivered directly into the nose, it is specifically designed to block infection at the portal of virus entry, and we believe it may help prevent transmission as well as provide protection against new COVID-19 variants.”
Their early studies at Washington University showed that nasal delivery of this vaccine creates a strong immune response throughout the body, especially in the nose and respiratory tract. In animal studies, the nasal vaccine entirely prevented infection from taking hold in the nose and lungs — suggesting that vaccinated individuals would be able to fend off the virus before it could multiply and cause an infection.
“Another advantage to a nasal vaccine is that it doesn’t require a needle,” Curiel said. “Many people who are willing to receive an injection are willing to inhale a vaccine. This vaccine also could be used to boost immunity in people who were previously vaccinated with any of the other vaccines. I think it could be very helpful in the ongoing effort to reduce SARS-CoV-2 infection and transmission here in the US and worldwide.”
Added Shankar Musunuri, PhD, chairman, CEO and co-founder of Ocugen: “Washington University’s COVID-19 nasal vaccine technology has been shown to induce strong mucosal immunity with potential to reduce SARS-CoV-2 infection, transmission and the emergence of new variants. As the effort to end the pandemic focuses on effective booster options, Ocugen is excited about the potential for this vaccine to be a universal booster, regardless of previous COVID-19 vaccination history. We look forward to working with US, European and Japanese regulators to expedite development.”
About Washington University School of Medicine
WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,700 faculty. Its National Institutes of Health (NIH) research funding portfolio is the fourth largest among US medical schools, has grown 54% in the last five years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,790 faculty physicians practicing at over 60 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children’s Hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.